Fig. 6: Treatment of Nlrp3D301N CreL mice with IL-18BP rescued highly inflammatory phenotype.
Nlrp3D301N CreL mice were treated with 6 μg/g rhIL-18BP (Tadekinig Alfa) or PBS from day 2 to 14. (A) Growth impairment, rash and reduced body weight, consistent with the phenotype of Nlrp3D301N CreL mice, were clearly normalized by IL-18BP treatment, whereas serum ALT did not significantly changed. (B) H&E- stained liver sections and quantification showing less inflammation in IL-18BP-treated mice. (C) Sirius Red-staining. (D) mRNA expression of extracellular matrix regulating enzymes (Timp1, Mmp10, Mmp13) were measured from total liver lysate. (E) Immunofluorescence staining and (F) quantification of PDGFR and αSMA showing more activated HSCs in the non-treated mice. (n = 5–6 mice per group for all measured values; scale bars represent 250 μm; *P < 0.05; **P < 0.01; ***P < 0.001).